Skip to main content
. 2022 Apr 25;198(1):82–92. doi: 10.1111/bjh.18183

FIGURE 2.

FIGURE 2

Response to BEGEV: (A) pre‐Nivolumab: appearance of new small adenopathies in the right latero‐cervical area and the left axillary area. DS5; (B) post‐Nivolumab: complete regression of the lesions previously present in the bilateral laterocervical area, subclavicular, mediastinal and pulmonary hilar areas. Complete response to treatment. DS3